There is a common skin disease that recurs and itchs violently during the attack. The skin is often scratched and often woke up by itch at night, which seriously affects daily life. After Ariah's recent treatment with a drug, his symptoms have been reduced by at least 75%.

has a common skin disease, which recurs and is severely itchy during the attack, and the skin is often scratched and is often awakened by itch at night, which seriously affects daily life. In some cases, applying creams and oral prescription drugs are often useless. Ariah is such a patient. After Ariah's recent treatment with a drug, his symptoms have been reduced by at least 75%.

-year-old Ariah started to have rash on multiple parts of the skin on her body since she was 2 years old. She was very itchy and was often scratched and broken. At night, she also often woke up itchy and caused insomnia , causing poor eating and bad temper.

Ariah was diagnosed with eczema in children. Apply various creams, oral anti-allergic drugs, and even consider oral steroid hormones and other immunosuppressive drugs.

Finally, Ariah received a drug for , and the eczema symptoms were reduced by at least 75% , and the itching was significantly reduced. What kind of drug is this? What is the scope of application?

1

—

What is atopic dermatitis ?

Currently, the common consensus in the dermatology community is: eczema , which was familiar to everyone in the past, is mostly atopic dermatitis .

atopic dermatitis, also known as atopic eczema. Atopic dermatitis is a common skin disease, with about 15%-20% of children and 5%-10% of adults suffering from this disease. The prevalence of atopic dermatitis in infants from 1 to 12 months can reach more than 30% . In recent years, atopic dermatitis in the elderly has gradually attracted attention.

Atopic dermatitis has chronic, recurrent, allergic characteristics, and the typical symptoms include Long-term dry skin , Repeated eczema-like rash and Strong itching . This itching is often unbearable, causing repeated scratches and skin breaks, wake up from itching at night, and itchy skin, which can also cause skin to become thicker and thicker, seriously affecting the quality of life.

2

—

General treatment of atopic dermatitis

Because atopic dermatitis has chronic recurrent characteristics, requires long-term treatment of , with the purpose of relieving or eliminating symptoms.

Reduce potential allergic irritation, topical moisturizing cream is the basic treatment of atopic dermatitis .

topical glucocorticoid cream is a first-line treatment for atopic dermatitis , including weak hydrocortisone cream to super potent 0.05% clobetasol cream. After the inflammatory symptoms are controlled, it can be transitioned to topical calcineurin inhibitors, such as tacrolimus cream. Zinc oxide oil agent, black bean distillate ointment , etc. also have certain effects. Patients who are prone to relapse need long-term topical cream maintenance treatment.

For those with obvious itching, consider taking antihistamines such as loratadine orally, and ultraviolet phototherapy can also be considered.
When the above conventional therapies are difficult to control, consider taking immunosuppressive drugs such as , such as , , etc.

For atopic dermatitis with mild symptoms, a large amount of moisturizing agents and low-tensioned glucocorticoid creams are often enough. However, for patients with moderate or severe symptoms, stronger glucocorticoid creams are difficult to control the symptoms.

In children, the proportion of moderate to severe patients is as high as 25%-40%. In this population, oral immunosuppressants “have potentially serious side effects.” Therefore, it is still necessary to seek drugs with clear effects and less side effects in patients with moderate to severe atopic dermatitis, especially in children.

3

—

biological treatment for atopic dermatitis

3-year-old Ariah finally received Dupilumab treatment.Dupilumab (Chinese name: degree primulambab , trade name: dabitu ) is a fully human monoclonal antibody that targets and inhibits the signaling of inflammatory factors. It is the only targeted biological agent in the world of that has been approved for the treatment of moderate to severe atopic dermatitis .

Dupilumab is jointly developed by Regenerative and Sanofi . In March 2017, the US FDA approved Dupilumab for the treatment of adult with moderate to severe eczema (atopic dermatitis). It was approved in 2019 for for children over 46 years old or adolescents. It was approved in June 2022 as the first biopharmaceutical for children with moderate to severe atopic dermatitis with 6 months to 5 years old.

In addition, Dupilumab has been approved by the Chinese CFDA for the treatment of moderate to severe atopic dermatitis in children, adolescents and adults aged 6 years and above.

4

—

How effective is Dupilumab?

Multiple Phase 3 clinical trial results show that whether it is adults, children or adolescents over 6 years old, patients with atopic dermatitis can significantly improve the itching symptoms within 2-5 days of using Dupilumab. After 16 weeks of use, the itching degree of can be reduced by about half, and the rash symptoms will be improved by about 70%.

4-year follow-up study found that using Dupilumab can continuously improve rash symptoms and rapidly and continuously improve patients' sleep quality. In the fourth year of treatment, the proportion of patients with rash symptoms improved by 75% was as high as 91%. As the use time of increases, patient satisfaction gradually increases to more than 80%.

022 On September 17, LANCET journal published the results of a randomized double-blind controlled trial of patients with atopic dermatitis with 6 months to 5 years old. It was found that at 16 weeks, the rash improved by more than 75% after using Dupilumab, and 48% of the patients had significantly reduced pruritus. Research believes that the use effect and adverse reactions of Dupilumab in children over 6 years old are similar to those of adults.

5

—

Dupilumab usage and adverse reactions?

html Children, adolescents and adults over 06 years old, Dupilumab is injected subcutaneously every 2 weeks, each dose is 300 mg, and the dose is 200 mg for those weighing less than 60kg, and the first dose is doubled.